Alternative dosing schedules for ustekinumab therapy

Kara HeelanDepartment of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland and Correspondence[email protected]

Saroj Marie VermaDepartment of Dermatology, Waterford Regional Hospital, Waterford, Ireland

Lesley-Ann MurphyDepartment of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland and

Michelle MurphyDepartment of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland and

Colin BuckleyDepartment of Dermatology, Waterford Regional Hospital, Waterford, Ireland

John F. BourkeDepartment of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland and

References

Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One. 2012;7:e33486
PubMed Web of Science ®Google Scholar
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–74
PubMed Web of Science ®Google Scholar
Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987–1019
PubMed Web of Science ®Google Scholar
Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–84
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Alternative dosing schedules for ustekinumab therapy

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Alternative dosing schedules for ustekinumab therapy

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date